Lambert G, Fattal E, Brehier A, Feger J, Couvreur P
Laboratoire de physico-chimie, pharmacotechnie et biopharmacie, URA-CNRS 1218, Faculté de Pharmacie, Châtenay-Malabry, France.
Biochimie. 1998 Dec;80(12):969-76. doi: 10.1016/s0300-9084(99)80002-9.
The aim of the present study was to evaluate the inhibitory effect on protein kinase C alpha (PKC alpha) neosynthesis of antisense oligonucleotides delivered by two types of carriers. First, PKC alpha antisense oligonucleotides were associated with polyisobutylcyanoacrylate (PIBCA) nanoparticles pre-coated with cetyltrimethyl ammonium bromide (CTAB), a hydrophobic cation. Adsorption of oligonucleotides onto PIBCA nanoparticles was shown to be a saturating process. From these studies, it was possible to identify two types of particles: positively and negatively charged. Secondly, Lipofectin was used as another carrier system. These systems were incubated with HepG2 cells. Toxicity was evaluated by the MTT assay, and PKC alpha neosynthesis was determined by Western blots in conditions where nanoparticles and Lipofectin were not inducing cytotoxicity. It was observed that both mismatch and antisense oligonucleotides induced an inhibition of PKC alpha neosynthesis when loaded onto cationic or anionic nanoparticles as well as when complexed to cationic liposomes (Lipofectin). This non-specific effect was only observed in the phase of PKC alpha neosynthesis when the cells were first depleted in PKC alpha by phorbol 12-myristate beta-acetate (12-PMA) and in the absence of serum. These results strongly suggest that delivery systems, PIBCA nanoparticles or Lipofectin, containing a positively charged component (CTAB or cationic lipids), are able to induce a perturbation in the intracellular metabolic activity. In conclusion, it was shown that the commonly used strategy of oligonucleotides targeting with cationic non-viral vectors may display non-specific effects which can lead to artifactual results.
本研究的目的是评估两种载体递送的反义寡核苷酸对蛋白激酶Cα(PKCα)新合成的抑制作用。首先,PKCα反义寡核苷酸与预先用疏水阳离子十六烷基三甲基溴化铵(CTAB)包被的聚异丁基氰基丙烯酸酯(PIBCA)纳米颗粒结合。寡核苷酸在PIBCA纳米颗粒上的吸附显示为一个饱和过程。从这些研究中,可以识别出两种类型的颗粒:带正电和带负电的。其次,脂质体转染试剂(Lipofectin)被用作另一种载体系统。这些系统与肝癌细胞系HepG2细胞一起孵育。通过MTT法评估毒性,并在纳米颗粒和Lipofectin不诱导细胞毒性的条件下,通过蛋白质免疫印迹法测定PKCα的新合成。观察到,当错配和反义寡核苷酸负载到阳离子或阴离子纳米颗粒上以及与阳离子脂质体(Lipofectin)复合时,均会诱导PKCα新合成的抑制。这种非特异性效应仅在PKCα新合成阶段观察到,此时细胞首先被佛波醇12 - 肉豆蔻酸酯β - 乙酸酯(12 - PMA)耗尽PKCα且无血清存在。这些结果强烈表明,含有带正电成分(CTAB或阳离子脂质)的递送系统,PIBCA纳米颗粒或Lipofectin,能够诱导细胞内代谢活性的扰动。总之,结果表明,使用阳离子非病毒载体靶向寡核苷酸的常用策略可能会显示非特异性效应,这可能导致人为结果。